Hendrikus J. Dubbink

Papers

Total Citations

H-Index

About

Hendrikus J. Dubbink is a leading molecular pathologist whose work is reshaping cancer diagnostics through the clinical implementation of next-generation sequencing. His primary research focuses on the validation and application of whole genome sequencing (WGS) and targeted gene panels for solid tumors, particularly in prostate and colorectal cancers. Dubbink’s landmark 2021 study, “Clinical Validation of Whole Genome Sequencing for Cancer Diagnostics” (86 citations), demonstrated that WGS using fresh-frozen tissue and matched blood samples can serve as a comprehensive, all-inclusive genetic test—a critical advance as biopsies shrink and the demand for multi-biomarker screening grows. He has also pioneered the use of RNA-based fusion detection and the analysis of homologous recombination repair defects, directly influencing precision oncology protocols. With over 5,000 total citations and a consistent record of high-impact publications in journals like *The Journal of Molecular Diagnostics* and *Modern Pathology*, Dubbink is recognized for bridging the gap between genomic technology and routine clinical care. His work not only improves diagnostic accuracy but also reduces turnaround times, making comprehensive genomic profiling more accessible for personalized cancer treatment.